newsfilter
← Latest News
GlobeNewswire·

Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathyAdvanced GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin